Jump to content

Covaxin - asalu adhi vaccine eh na ?


coffee

Recommended Posts

  1. How was the vaccine candidate approved without efficacy data – i.e. without any data from phase 3 clinical trials?
  2. Where are the minutes of the meeting that deliberated on Bharat Biotech’s application and Covaxin’s eventual approval?
  3. What does the language the Drug Controller General of India (DCGI) used to approve Covaxin really mean, considering they appear to have been a bit of creative writing?

In fact, as the DCGI was approving the vaccine candidates, one more controversy erupted: AIIMS Delhi director Dr Randeep Guleria said that based on the 24,000 or so participants who had received one dose of Covaxin in its phase 3 trials, the vaccine has been found to be safe. This was a reckless remark that only heightened doubts. For example, did this mean researchers had broken the trial’s blind – i.e. knew who had received the vaccine and who had received the placebo

  • Haha 1
  • Upvote 1
Link to comment
Share on other sites

India launches what could be the world’s largest vaccination campaign. But it’s unclear if one of the vaccines works.

A hospital staff member administers a Covishield vaccine, developed by Oxford-Astrazeneca and manufactured by Serum Institute of India Ltd., at the Ganga Ram Hospital in New Delhi. A hospital staff member administers a Covishield vaccine, developed by Oxford-Astrazeneca and manufactured by Serum Institute of India Ltd., at the Ganga Ram Hospital in New Delhi. (T. Narayan/Bloomberg News)
Link to comment
Share on other sites

Only the Oxford-AstraZeneca vaccine has completed a Phase 3 clinical trial for safety and efficacy. Bharat Biotech has finished earlier-stage trials on its vaccine but has provided no data on whether it works. Yet both vaccines are being administered, and people cannot choose which vaccine they receive.

Link to comment
Share on other sites

Asia Today: India starts shipping COVID-19 vaccine to cities

Health workers shift a box containing COVID-19 vaccine from a vehicle to a cold storage at Commissionerate of Health and Family Welfare in Hyderabad, India, Tuesday, Jan. 12, 2021. On Jan. 16 India will start the massive undertaking of inoculating an estimated 30 million doctors, nurses and other front line workers, before attention turns to around 270 million people who are either aged over 50 or have co-morbidities. Health workers shift a box containing COVID-19 vaccine from a vehicle to a cold storage at Commissionerate of Health and Family Welfare in Hyderabad, India, Tuesday, Jan. 12, 2021. On Jan. 16 India will start the massive undertaking of inoculating an estimated 30 million doctors, nurses and other front line workers, before attention turns to around 270 million people who are either aged over 50 or have co-morbidities. (Mahesh Kumar A./Associated Press)
By Associated Press
Jan. 12, 2021 at 12:15 a.m. EST

NEW DELHI — India has started shipping COVID-19 vaccines to multiple cities, four days ahead of a nationwide inoculation drive.

The first consignment of vaccines developed by the Serum Institute of India left the city of Pune on Tuesday. The vaccines rolled out from Serum Institute of India’s facility in temperature-controlled trucks to the city’s airport, from where they were loaded into private air carriers for distribution all over the country.

Link to comment
Share on other sites

2 minutes ago, coffee said:

Only the Oxford-AstraZeneca vaccine has completed a Phase 3 clinical trial for safety and efficacy. Bharat Biotech has finished earlier-stage trials on its vaccine but has provided no data on whether it works. Yet both vaccines are being administered, and people cannot choose which vaccine they receive.

Even Astrazenca US is not giving approval as they botched 3rd phase dosages for participants.

Link to comment
Share on other sites

Bharat Biotech to pay compensation if Covaxin causes side effects

The vaccine maker said in phase 1 and phase 2 clinical trials, Covaxin has demonstrated the ability to produce antidotes against COVID- 19

Posted: Jan 16, 2021 03:28 PM   Updated: 1 min ago

Beautiful Image

Indian Health Minister Harsh Vardhan holds a dose of Bharat Biotech's COVID-19 vaccine called COVAXIN, during a vaccination campaign at All India Institute of Medical Sciences (AIIMS) in New Delhi on Saturday. REUTERS

Hyderabad, January 16

Bharat Biotech, which has received a government purchase order for supply of 55 lakh doses of Covaxin, a COVID-19 vaccine, said the company would pay compensation to recipients in case of any serious adverse effects experienced after receiving the antidote.

In the consent form to be signed by the vaccine recipients, Bharat Biotech said: “In case of any adverse events or serious adverse events, you will be provided medically recognised standard of care in the government designated and authorised centres/hospitals.”

“The compensation for serious adverse event will be paid by sponsor (BBIL) in case if the SAE is proven to be causally related to the vaccine,” the consent form said.

Link to comment
Share on other sites

1 minute ago, RunRaajaRun123 said:

Even Astrazenca US is not giving approval as they botched 3rd phase dosages for participants.

Thanks they r not giving approval..but in india health minister and government themselves are promoting 

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

×
×
  • Create New...